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The majority of supratentorial ependymomas (ST-
ependymomas) have few mutations but frequently
display chromothripsis of chromosome 11q that
generates a fusion between C11orf95 and RELA
(RELAFUS). Neural stem cells transduced with
RELAFUS ex vivo form ependymomas when im-
planted in the brain. These tumors display enhanced
NF-kB signaling, suggesting that this aberrant signal
is the principal mechanism of oncogenesis. How-
ever, it is not known whether RELAFUS is sufficient
to drive de novo ependymoma tumorigenesis in the
brain and, if so, whether these tumors also arise
from neural stem cells. We show that RELAFUS drives
ST-ependymoma formation from periventricular
neural stem cells in mice and that RELAFUS-induced
tumorigenesis is likely dependent on a series of cell
signaling pathways in addition to NF-kB.INTRODUCTION
Ependymomas account for 10% of intracranial tumors in chil-
dren and 4%of brain and spinal cord tumors in adults (Chamber-
lain, 2003; Ruda` et al., 2008). Genomic studies have subdivided
supratentorial (ST), posterior fossa (PF) and spinal (SP) ependy-
momas into clinically meaningful and molecularly distinct sub-
groups (Johnson et al., 2010; Mack et al., 2014; Pajtler et al.,
2015; Parker et al., 2014; Taylor et al., 2005; Witt et al., 2011).
Despite these insights, all ependymomas are similarly treated
with surgery and radiotherapy. Chemotherapy is not usedCell
This is an open access article under the CC BY-Nroutinely to treat ependymoma because it is largely ineffective
(Bouffet and Foreman, 1999; Merchant et al., 2009).
Recent next-generation sequencing studies have discovered
recurrent chromosomal translocations in a subset of ST-ependy-
momas that generate distinct fusion oncogenes (Parker et al.,
2014). Seventy-two percent of ST-ependymomas contain
C11orf95-RELA fusions (Pajtler et al., 2015; Parker et al.,
2014). Patients with these tumors have a 5-year progression-
free survival of <30% (hereafter termed the ST-ependymoma
[EPN]-RELA subtype). A further 10% of ST-ependymomas
contain either C11orf95-YAP1, YAP1-MAMLD1, or YAP1-
FAM118B fusions (ST-EPN-YAP1 subtype) and have a much
better 5-year progression-free survival of 66% (Pajtler et al.,
2015; Parker et al., 2014). RELA and YAP1 fusions are highly
restricted to ST-ependymomas, supporting the notion that
regional neural cell types are uniquely susceptible to specific ge-
netic mutations (Johnson et al., 2010; Mohankumar et al., 2015;
Taylor et al., 2005). The remaining 18% of ST-ependymomas are
subependymomas that lack fusion genes and have an excellent
clinical outcome (Pajtler et al., 2015; Parker et al., 2014).
We showed recently that the two most common C11orf95-
RELA fusions (RELAFUS1 and RELAFUS2) and C11orf95-YAP1
(but not C11orf95, RELA, or YAP1 alone) can transform embry-
onic mouse neural stem cells ex vivo (Parker et al., 2014).
Although expression of RELAFUS1was shown to activate nuclear
factor kB (NF-kB) signaling, whether this is required for trans-
formation and whether fusions can drive ependymomagenesis
de novo in the brain is not known. To test this, we used the
RCAS/tv-a system to deliver the RELAFUS1 fusion or fusion vari-
ants engineered to contain mutations in critical portions of RELA
to Nestin-, glial fibrillary acidic protein (GFAP)-, or BLBP-ex-
pressing cells in the mouse brain. Neither C11orf95 nor RELA
alone were sufficient to drive tumorigenesis. Expression ofReports 23, 3787–3797, June 26, 2018 ª 2018 The Author(s). 3787
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Somatic Cell Gene Transfer of C11orf95-RELA into Nestin-Expressing Cells Drives Brain Tumorigenesis
(A) Schematic of various RCAS vectors. Blue and red boxes represent components of C11orf95 and RELA coding sequences, respectively. Z, zinc finger (C2H2-
like); RHD, Rel homology domain; AD, activation domain; orange box, 9aaTAD; H, HA tag. The phosphorylation and acetylation sites of the RELAFUS1 gene
product corresponding to those of RELA are also described.
(B) Kaplan-Meier survival curves showing symptom-free survival of RCAS-RELAFUS1 (black line) andRELAFUS1-HA (red line),RELA-HA (blue line), orC11orf95-HA
(green line) injection inNestin (N)/tv-a (regular line) orN/tv-a;Ink4a-Arf/ (dotted line) mice. Tumor formation was observed by injection of these RCAS viruses into
neonatal pups brains. n.s., not significant.
(C) Summary of the RCAS vector injections in N/tv-a or N/tv-a;Ink4a-Arf/mice.RELAFUS1 in our system upregulated a broad array of genes that
included an NF-kB-associated transcriptional signature; how-
ever, RELAFUS1 mutants with selective mutation of the Rel ho-
mology domain (RHD) as well as constitutively active RELA mu-
tants failed to induce brain tumor formation. The data suggest
that RELAFUS1 is adequate to drive EPN formation de novo in
the brain. The oncogenic effect of RELAFUS1 requires the Ser
486, but not Ser 746, phosphorylation site in the fusion protein
and produces biologic effects that are not restricted to NF-kB.
RESULTS
C11orf95-RELA Drives Brain Tumorigenesis
RELAFUS1 accounts for almost half of all C11orf95-RELA fusions
and includes the N-terminal portion of C11orf95 and all but the
first two codons of RELA (Parker et al., 2014). To test the ability
ofRELAFUS1 to form ependymomas de novo, we used the RCAS/
tv-a system to express RELAFUS1 in specific brain cell types in
mice (Holland et al., 1998; Holland and Varmus, 1998). RCAS-
RELAFUS1 or RCAS-RELAFUS1-HA (containing a C-terminal hu-
man influenza hemagglutinin [HA] tag) were first expressed in
Nestin-expressing brain cells using Nestin (N)/tv-amice (Figures
1A and S1; Holland et al., 1998). Fifty-two percent and 92%
of mice injected with RCAS-RELAFUS1 or RCAS-RELAFUS1-HA,
respectively, but not a control, developed tumorswithin 2months
of injection (Figures 1A–1C; Table S1A). In stark contrast,
RCAS-HA-RELA, RCAS-RELA-HA, or RCAS-C11orf95-HA
failed to generate tumors, confirming our prior observations
that RELAFUS1, but neither translocation partner gene alone, is
competent to drive tumorigenesis (Figures 1A–1C andS1; Parker3788 Cell Reports 23, 3787–3797, June 26, 2018et al., 2014). Notably, although CDKN2A (INK4A-ARF) is deleted
in some ST-EPN-RELA tumors and enhances platelet-derived
growth factor (PDGF)-induced glioma formation in mice,
RELAFUS1-induced tumorigenesis neither required, nor was it
accelerated by, Ink4a-Arf deletion in mice (Figures 1B and 1C;
Table S1B; Fomchenko et al., 2011; Ozawa et al., 2014; Pajtler
et al., 2015).
RELAFUS1-Induced Mouse Tumors Recapitulate ST-EPN
Histology
RELAFUS1-induced tumors were well circumscribed, predomi-
nantly intra-ventricular tumors that displayed several histological
features characteristic of ependymoma, including a biphasic
architectural pattern of dense cell clusters alternating with hypo-
cellular regions and relatively little necrosis (Figures 2A and S2A)
but no canonical ependymal rosettes and pseudorosettes,
although similar structures were sometimes observed (Fig-
ure 2B). RELAFUS1-induced tumors also contained a network of
delicate branching capillaries similar to that observed in our
ex vivo RELAFUS1-induced tumor model (Parker et al., 2014)
and the vascular variant of human ST-ependymomas (Figure 2B;
Figarella-Branger et al., 2016; Godfraind et al., 2012; Rousseau
et al., 2007). These morphological findings were obviously
distinct from both astrocytic and oligodendrocytic gliomamouse
models and human glioblastoma (GBM) presenting an infiltrative
growth pattern and glomeruloid microvascular formation (Fig-
ures 2A and 2B and S2B–S2F). Immunostaining and electron mi-
croscopy of RELAFUS1-induced tumors identified additional fea-
tures common to human ependymomas, including expression of
GFAP andOlig2 and interdigitating tumor cell processes (Figures
Figure 2. RELAFUS1-Induced Mouse Tumors Recapitulate Human ST-EPN Histology
(A) Representative H&E and immunohistochemistry (IHC) images of RCAS-RELAFUS1-HA-, PDGFA-, and GPT53N-induced brain tumors in the indicated tv-a
mice. HA, PDGFA, and GFP antibody immunoexpression represents essentially the vector expression. Dashed boxes at the top denote the enlarged regions as
shown at the bottom. Scale bars, 100 mm.
(B) Representative H&E stainings of RELAFUS1-induced brain tumors inN/tv-a;Ink4a-Arf/mice, human RELAFUS1-positive ST-ependymoma, and human GBM.
Scale bars, 100 mm.
(C) Representative H&E and IHC analysis with the indicated antibodies of RCAS-RELAFUS1-induced brain tumors inN/tv-amice. All enlarged images represent the
areas of dashed boxes in H&E staining. Scale bars, 100 mm.
(D) Representative ultra-structure of a RELAFUS1-induced brain tumor. Black arrowheads show interdigitating tumor cell processes.2C and 2D and S2E and S2F; Liberski, 1996; Otero et al., 2011).
Furthermore, we showed previously that human ST-EPN-RELA
tumors display intense nuclear RELA immunoreactivity (Parker
et al., 2014). The same immunohistochemical feature was dis-
played by our de novo RELAFUS1-induced tumors but not by
similarly generated PDGFA- or shNf1 (GPT53N)-driven mouse
gliomas (Figure 3A). These observations were further validated
in a cohort of human ST- (n = 23), PF- (n = 49), and SP-ependy-
momas (n = 48) and GBMs (n = 30) (Figures 3B and 3C and
S3A–S3E; Tables S2A–S2C). Thus, our RELAFUS1-induced brain
tumors recapitulate the principal growth, morphological, and
immunohistochemical features of human ST-EPN-RELA tumors.
RELAFUS1-Induced Mouse Tumors Express a Human ST-
EPN-RELA-like Transcriptome
To further assess the fidelity of theRELAFUS1-EPNmousemodel,
we performed RNA sequencing (RNA-seq) analysis of these tu-
mors and compared their transcriptomes with those of normal
mouse brain and PDGFA-driven mouse gliomas (Table S3).
Principal-component analysis clearly segregated RELAFUS1-
ependymoma, PDGFA-driven glioma, and normal brain tran-scriptomes, confirming the distinct biologies of these tissues
(Figure 4A). Next, to test whether RELAFUS1-driven mouse tran-
scriptomes recapitulate those of human ST-EPN-RELA, we
compared their transcriptomes using cross-species gene set
enrichment analysis (GSEA) (Supplemental Experimental Pro-
cedures). Gene sets that define human ST-ependymoma, and
in particular ST-EPN-RELA, but not human PF- or SP-ependy-
moma, were significantly enriched in mouse RELAFUS1-driven
tumor transcriptomes (Figures 4B–4E; Pajtler et al., 2015; Taylor
et al., 2005). Thus, in addition to displaying the morphologic and
immunophenotypic characteristics of ST-EPN-RELA,RELAFUS1-
ependymomas also recapitulate the transcriptome of human ST-
EPN-RELA.
We showed previously that RELAFUS1 translocates spontane-
ously to the nucleus of mouse neural stem cells to activate the
transcription of a large number of genes, including NF-kB target
genes (Parker et al., 2014). In keeping with these data, genes
that were significantly upregulated in de novo RELAFUS1-induced
mouse ependymomas relative to normal brain included 52%
(n = 158 of 302) of validated NF-kB target genes (false
discovery rate [FDR] p = 4.7 3 107), and GSEA identifiedCell Reports 23, 3787–3797, June 26, 2018 3789
Figure 3. RELA Expression in Mouse and Human RELAFUS1 EPNs
(A) Representative IHC analysis for RELA of RCAS-RELAFUS1-, PDGFA-, and GPT53N-induced brain tumors in the indicated tv-amice. Dashed boxes at the top
denote the enlarged regions as shown at the bottom. Scale bars, 100 mm.
(B) Representative H&E and IHC analysis for RELA of human RELAFUS1-positive (ST203, ST214) and RELAFUS1/2-negative (ST218) ST-ependymomas and
PF-EPN (PF232). All IHC images show the same area as each H&E images. Scale bars, 100 mm.
(C) Summary of semiquantitative immunohistochemical analysis for RELA in human ependymomas and GBMs. The immunoexpression level was evaluated using
two criteria: nuclear immunoreactivity (NucIR) and staining intensity as described in Figure S3D and Table S2B.
See also Supplemental Experimental Procedures.‘‘TNFA_signaling_via_NFKB’’ as one of the most enriched gene
sets in these tumors (FDR, q value 6.39 3 1043). Furthermore,
hierarchical clustering using validated NF-kB target genes alone
readily segregated de novomouseRELAFUS1-EPN (EP), PDGFA-
driven glioma (GM) and normal mouse brain (NB) transcriptomes
(Figure 4F). Thus, RELAFUS1 activates NF-kB target gene tran-
scription following de novo tumor formation in vivo as well as in
neural stem cells in vitro.
RELAFUS1 Induces an Aberrant Non-Canonical NF-kB
Transcriptional Cassette
Although overexpression of wild-type RELA in neural stem cells
activates gene transcription, this is restricted to NF-kB target
genes and does not promote malignant transformation (Figures
1B and 1C; Tables S1A–S1D; Parker et al., 2014). Thus, aberrant
NF-kBsignaling appears to be associatedwith, but not sufficient,
to drive RELAFUS1-induced tumorigenesis. Therefore, to better
understand how RELAFUS1 drives transformation, we looked for
non-NF-kB target genes that were dysregulated in both our
ex vivo and de novo RELAFUS1-induced mouse ependymomas.
Nine thousand nine hundred and sixty-five genes were signifi-
cantly up- or downregulated in either our ex vivo neural stem3790 Cell Reports 23, 3787–3797, June 26, 2018cell (Parker et al., 2014) or de novo RELAFUS1-induced mouse
brain tumors relative to mouse normal neural stem cells and
brain, respectively (p < 0.05 FDR). A significant number of these
genes was commonly dysregulated in both tumors, including
13% that were upregulated (n = 1,271 of 9,965) and 4% that
were downregulated (n = 400 of 9,965) in both tumor models
(p = 2.3 3 106 for overlap) (Table S4). Only 6% of these genes
(n = 102 upregulated, n = 1 downregulated) are known NF-kB
targets (Table S4A). GSEA segregated the remaining 1,568
‘‘non-NF-kB’’ target genes into nine broad classes (Table S4B).
Remarkably, we showed previously that six of these classes
are dysregulated when mouse neural stem cells are transformed
by non-fusion EPN oncogenes (Mohankumar et al., 2015). These
included negative enrichment of synaptogenesis and vesicle
trafficking regulators (e.g., INTRACELLULAR_VESICLE, n = 137
of 1,259, FDR q value = 2.843 1051), consistent with our obser-
vation that these genes are selectively deleted during ST-EPN
tumorigenesis (Mohankumar et al., 2015). The five other
gene classes commonly enriched with those in non-RELAFUS1
EPN included stem cell function and neuronal differentiation
(e.g., REGULATION_OF_CELL_DIFFERENTIATION, n = 160 of
1,492, FDR q value = 3.20 3 1059), immunity and inflammation
Figure 4. RELAFUS1-Induced Mouse Tumors
Express a Human ST-EPN-RELA-like Tran-
scriptome
(A) Principal-component analysis with gene
expression profiling of RELAFUS1 ependymomas,
PDGFA-driven murine gliomas, and normal mouse
brains.
(B–E) Gene set enrichment analysis (GSEA) of
RELAFUS1 ependymomas and PDGFA-induced
gliomas. Gene expression profiles were compared
between both mouse tumor types using gene sets
based on ST- (B), PF- (C), and SP-EPN (D) or ST-
EPN-RELA’s (E) gene expression signatures (Paj-
tler et al., 2015; Taylor et al., 2005). The nominal
p value (NOM p-val) and false discovery rate
(FDR)-corrected q value (FDR q-val) are indicated.
A nominal p value of <0.05 was considered sig-
nificant in this analysis.
(F) Unsupervised hierarchical cluster analysis of 302
validated NF-kB target genes expressed de novo
in mouse RELAFUS1-EPN (EP), PDGFA-driven gli-
oma (GM), and normal mouse brain (NB) (http://
www.bu.edu/nf-kb/gene-resources/target-genes/;
T. D. Gilmore; Parker et al., 2014).(e.g., REGULATION_OF_CYTOKINE_PRODUCTION, n = 114
of 563, FDR q value = 8.71 3 1069), the epigenome
(SILENCED_BY_METHYLATION, n = 67 of 282, FDR q value =
6.14 3 1047), and those associated with other cancer types.
Notably, this latter class included positive enrichment of genes
associated with the mesenchymal subtype of glioblastoma
(GLIOBLASTOMA_MESENCHYMA, n = 95 of 216, FDR q value =
2.263 1095). By addition to these six broad classes, RELAFUS1-
induced transformation also enriched the expression of genes
controlling cell-cell adhesion (e.g., BIOLOGICAL_ADHESION,
n = 155 of 1,032, FDRq value = 4.273 1075) and downregulated
genes controlling the transmembrane transport of ions
(e.g., ION_TRANSPORT, n = 45 of 1,262, FDR q value =
1.23 3 1012) that we did not observe during the formation of
non-RELAFUS1 EPN (Mohankumar et al., 2015). Together, these
data suggest that all forms of ST-ependymomagenesis require
dysregulation of synaptogenesis and vesicle trafficking, stem
cell function and neuronal differentiation, immunity and inflam-
mation, the epigenome, and functions associatedwith other can-
cer types; however, dysregulation of cell-cell adhesion and ion
transport might be associated more selectively with RELAFUS1-
induced transformation.Cell RBecause loss of Ink4a-Arf did not affect
the tumor latencyofourRELAFUS1-induced
ependymomas,we investigated the dysre-
gulation of alternative pathways. Accumu-
lation of TP53 is very frequent in human
ST-EPN-RELA tumors and associated
with a poor prognosis, although this gene
mutation is rare (Tzaridis et al., 2016).
Furthermore, the accumulated TP53 is
thought tobe functionally impaired inepen-
dymomas (Gaspar et al., 2006; Tzaridis
et al., 2016; Verstegen et al., 2002). There-fore, we focused on Trp53 status in themouse tumors. Consistent
with frequent accumulation of TP53 in human RELAFUS-positive
cases (Tzaridis et al., 2016), evident upregulation of the Trp53
pathway and elevated Trp53 mRNA expression were observed
in RELAFUS1-induced tumors in both N/tv-a and N/tv-a; Ink4a-
Arf/ mice (Figures S4A–S4). Thus, it is possible that the effect
of Ink4a-Arf loss inRELAFUS1-induced EPN formation was blurred
by dysregulation of the TP53 pathway in our model, leading to no
survival difference between the genetic backgrounds (Figures 1B
and 1C).
Serine-486 of RELAFUS1 (Corresponding to Serine-276of
RELA) Is Critical to Drive Tumorigenesis
The aberrant juxtaposition of genes within fusion proteins
following chromosomal translocation may result in the uncon-
trolled activation of fusion partners or the acquisition of novel
functions (Mertens et al., 2015). Our transcriptomic analyses
of RELAFUS1-driven tumors suggest that this fusion activates
NF-kB signaling and a series of other cell pathways. Therefore,
to further dissect the NF-kB- and non-NF-kB-related trans-
forming functions of RELAFUS1, we created a series of mutant
forms of wild-type RELA and RELAFUS1 and tested the capacityeports 23, 3787–3797, June 26, 2018 3791
Figure 5. Serine-486 of RELAFUS1 Is Critical
to Drive Tumorigenesis
(A and B) Kaplan-Meier survival curves showing
symptom-free survival of RELAFUS1-HA or
RELAFUS1-HA mutant-induced brain tumors in
N/tv-a (A) and N/tv-a; Ink4a-Arf/ (B) mice. The
survival curves of the RELAFUS1-HA-induced tu-
mors from Figure 1B are also shown for compari-
son. Statistical comparison of each mutant
with RELAFUS1-HA is also shown in the legends
and Table S1C. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
(C) Tumor incidence ofRELA-HA,RELAFUS1-HA, or
the relevant mutant injection in N/tv-a and N/tv-
a;Ink4a-Arf/mice.
See also Tables S1A–S1C.of these constructs to drive tumorigenesis in our RCAS/tv-a
system in vivo. Phosphorylation of Ser-276 and Ser-536 within
the Rel homology and transactivation domains, respectively,
has been reported to promote RELA transcriptional activity
(Figure 1A; Chen and Greene, 2004; Hoesel and Schmid,
2013; Huang et al., 2010); however, introduction of phosphomi-
metic mutants of these residues (RELA-S276E, RELA-S536E,
or combined RELA-S276E/S536E) into the brains of N/tv-a
and N/tv-a;Ink4a-arf/ neonatal mice failed to drive tumorigen-
esis (Figures 1A and S5A; Tables S1A and S1B). Thus, consis-
tent with our studies of overexpressed wild-type RELA (Parker
et al., 2014), constitutively active RELA is not competent to
drive ependymomagenesis.
We next created a series of RELAFUS1 mutants and tested
the ability of these to drive ependymomagenesis in the brains
of N/tv-a and N/tv-a;Ink4a-arf/ neonatal mice (Figures 1A
and S5B–S5D). A serine-glutamine substitution at Ser-486 of
RELAFUS1 (corresponding to Ser-276 in the Rel homology domain
of RELA) markedly reduced the transforming capacity of
RELAFUS1 (Figures 1A and 5A–5C; Tables S1A–S1C); RELAFUS1-
S486E formed no tumors in 14 N/tv-a neonatal brains compared
with a tumor penetrance of 92% (n = 33 of 36) in mice injected
with RELAFUS1 (log ratio, p = 0.0009) (Figure 5C; Tables S1A and
S1C). RELAFUS1-S486E-driven tumor penetrance was also much
reduced in N/tv-a;Ink4a-arf/ neonatal mice (8%, n = 1 of 12)
compared with 86% (n = 24 of 28) driven by RELAFUS1 (log ratio,
p = 0.0095) (Figure 5C; Tables S1B and S1C). In contrast, a
serine-glutamine substitution at Ser-746 (corresponding to Ser-
536 of RELA) did not reduce tumorigenesis in either N/tv-a or
N/tv-a;Ink4a-arf/ neonatal mice (Figures 1A and 5A–5C; Tables
S1A–S1C). Constructs harboring both of these substitutions
(RELAFUS1-S486E/S746E: EE) failed to drive tumorigenesis in the
N/tv-a neonatal brain and drove tumors with a penetrance of
only 12%(n=4of 33) inN/tv-a;Ink4a-arf/ neonatalmice (Figures
5A–5C; Tables S1A–S1C), suggesting that S486E had a negative
effect on thebrain tumor-formingcapacityofRELAFUS1. Twoaddi-
tional constructs carrying serine-alanine substitutions at these3792 Cell Reports 23, 3787–3797, June 26, 2018same residues (RELAFUS1-S486A and
RELAFUS1-S486A/S746A: AA) also abol-
ished and markedly reduced RELAFUS1-driven ependymomagenesis in N/tv-a (S486A, log rank test,
p = 0.0006; S486A/S746A, log rank test, p = 0.1731) and N/tv-a;
Ink4a-arf/ (S486A, log-rank test, p = 0.0004; S486A/S746A,
log-rank test, p = 0.0024) neonatal mouse brains, respectively
(Figures 5A–5C; Tables S1A–S1C), whereas RELAFUS1-S746A
did not affect tumorigenesis. Thus, Ser-486, but not Ser-746, ap-
pears to be critical for RELAFUS1-driven ependymomagenesis.
Acetylation of RELA has also been reported to regulate NF-kB
activity (Huang et al., 2010). Acetylation of lysine-310 (K310) has
been reported to promote full transcriptional activity (Chen et al.,
2002; Huang et al., 2010), and K221/K218 acetylation enhances
DNA binding and prevents nuclear export. To test the impor-
tance of these residues in RELAFUS1-driven tumorigenesis, we
generated lysine-to-arginine unacetylatable mutants in the
residues corresponding to K218, K221, and K310R of RELA
(RELAFUS1-K428R/K431R/K520R: 3KR; Figures 1A, S5B, and
S5E; Chen et al., 2002). RELAFUS1-3KR drove ependymomas
with high penetrance in N/tv-a (84%, n = 21/25) and N/tv-a;
Ink4a-Arf/ (83%, n = 29 of 35) mice, indicating that acetylation
of these residues is dispensable forRELAFUS1-driven tumorigen-
esis (Figures 5A-5C; Tables S1A–S1C).
Disruption of Cell-Cell Adhesion Is a Critical Component
of RELAFUS1-Driven Tumorigenesis
We reasoned that comparing the transcriptomes driven by
RELAFUS1 mutants that did or did not drive tumorigenesis
might pinpoint cell functions that are critically associated with
RELAFUS1-driven transformation. Multi-dimensional scaling
(MDS)usingNF-kB targetgenesas input (TablesS5andS6)clearly
segregated NIH 3T3/tv-a cells transduced with tumor-forming
vectors (RELAFUS1, RELAFUS1-S746E, and RELAFUS1-3KR) from
those transduced with non-transforming constructs (RELA-
S276E, RELAFUS1-S486E, and RELAFUS1-EE), strongly suggesting
that NF-kB activity is significantly associated with RELAFUS1-
driven tumorigenesis (Figures 6A, S6A, and S6B). More than half
of these genes were enriched for regulators of cell-cell adhesion
and the extracellularmatrix, immunity and inflammation, or vesicle
Figure 6. RNA-Seq Analysis of NIH3T3T Cells and RELAFUS1-Induced Mouse Tumors
(A) Multidimensional scaling (MDS) projection of sample similarities based on gene expression profiling analyzed with the NF-kB gene set in NIH 3T3T cells
infecting the indicated RCAS vectors. See also Tables S5, S6, and S7.
(B) Boxplots of PDGFB, PDGFRB, and PDGFRA expression in mouse brain and brain tumor tissues. See also Table S3.trafficking (Table S4B). Thus, RELAFUS1 might drive EPN tumori-
genesis in part by dysregulating communication between tumor
cells and the brain microenvironment, perhaps promoting local in-
vasion and growth (Mohankumar et al., 2015).
Interestingly, in addition to these gene sets, both PDGF beta
polypeptide (PDGFB) and its cognate receptor PDGF beta poly-
peptide (PDGFRB) were markedly upregulated in the transcrip-
tomes of RELAFUS1-driven ex vivo and de novo ependymomas
(Figure 6B; Parker et al., 2014) as well as selectively upregulated
in those driven by tumorigenic RELAFUS1 mutants (Table S7).
PDGFB is a highly potent neural oncogene (Dai et al., 2001);
thus, RELAFUS1 might also drive EPN tumorigenesis by upregu-
lating oncogenic PDGFB-PDGFRB signaling.
The Normal Ventricular Wall as the Putative Location for
Ependymomagenesis
Our prior cross-species analyses and ex vivo mouse modeling
predict that neural stem cells in the lateral ventricular wall are
cells of origin of EPN (Johnson et al., 2010; Mohankumar et al.,
2015; Taylor et al., 2005). However, these studies involved
cross-species mapping of human EPN gene expression profiles
in normal developing mouse brain or ex vivo transduction of
mouse neural stem cells that form tumors when reimplanted in
the brain. Therefore, to better understand the origin of ependy-
moma, we took advantage of our de novo RELAFUS1-induced tu-
mor model. These tumors were typically observed as intra- and/
or peri-ventricular cerebral masses, although, rarely, tumors also
occurred in the cerebral parenchyma not obviously connected
with the ventricular system, similar to the growth pattern of hu-
man ependymomas (Figures 2A, 2C, 3A, S2A, and S7A–S7E).
Histological analyses of early lesions developing within 31 days
of RELAFUS1 injection into N/tv-a mice identified small lesions
immediately adjacent to the ventricular system (Figures 7A
and S7E).
To further understand the cellular origin of ependymoma, we
tested the capacity of mice harboring different tv-a transgenes
to develop RELAFUS1-driven ependymoma. N/tv-a used in theexperiments described above specifically targets nestin-ex-
pressing neural stem and progenitor cells. Therefore, we investi-
gated the oncogenic potential of the RELAFUS1 gene in neonatal
mouse brains when it is targeted to GFAP-expressing cells using
(G)/tv-a- (Holland and Varmus, 1998) or BLBP (brain lipid binding
protein, also known as fatty acid binding protein 7 or FABP7)-
expressing cells using a (B)/tv-a transgenic mouse in which an
expression of tv-a, a receptor for RCAS virus, was driven under
a GFAP or BLBP promoter, respectively (Figures S7F–S7H).
Tumors occurred in both of these transgenic lines with similar
histologic features as those forming in theN/tv-amice (or human
ST-EPN) (Figures 7B and 7C; Table S1D). These data further
support the notion that Nestin-, GFAP-, and BLBP-expressing
neural stem and progenitor cells in the ventricular wall can serve
as cells of origin of RELAFUS1-induced ST-ependymoma.
DISCUSSION
Unlike GBM with its multiple sequence and copy number alter-
ations, the genome of humanST-EPN is relatively stable but con-
tains a fusion gene that is sufficient to induce similar tumors in
mice. Therefore, human ST-EPN may follow a single-hit onco-
genesis model such as BCR-ABL-driven chronic myelogenous
leukemia (CML) (Groffen et al., 1984). The oncogenic function
of theRELA or YAP1 fusion products in ST-EPN is not yet known,
and it may or may not be easily targeted with small molecules.
Genetically accurate mouse models of this disease will certainly
help with the development of such therapies should they
become available.
The location of the cell of origin ofRELAFUS1-EPN in themouse
seem to be at the edge of the subventrical zone (SVZ), consistent
with what onemight imagine for human ST-ependymoma. At this
point, it is not clear whether the oncogenic function of this fusion
protein occurs in the nucleus or cytoplasm. When it comes to
the driving functions of the RELA fusion products, RELAFUS1
does have NF-kB activity, but it is worth noting that neither the
individual components of or activated versions of RELA formCell Reports 23, 3787–3797, June 26, 2018 3793
Figure 7. The Normal Ventricular Wall as the Putative Location for Ependymomagenesis
(A) Representative IHC images of the HA tag of RCAS-RELAFUS1-HA-induced brain tumors in N/tv-a mice (see also Figure S7E). Brain tumor formation was
examined with HA tag staining 1 month post-injection. Dashed circles at the top show early lesions representing, essentially, RCAS vector expression. Red
dashed circles denote the enlarged regions as shown at the bottom. Scale bars, 200 mm.
(B and C) Representative H&E and IHC images for RELA of RELAFUS1 or RELAFUS1-HA-induced brain tumors in GFAP(G)/tv-a (B) or BLBP(B)/tv-a mice (C).
Enlarged areas for H&E and RELA are shown as a dashed box in each H&E brain. Scale bars, 100 mm.
(D) Summary of RCAS-RELAFUS1 or RELAFUS1-HA vector injections in G/tv-a or B/tv-a mice.ependymomas. Several lines of evidence suggest that the onco-
genic driving functions of RELA fusion products may be more
than aberrant NF-kB activity. We found that RELAFUS1 drives
several other biological processes, including vesicular transport,
development of cytokine production, and cell-cell adhesion. The
importance of cell-cell adhesion in the oncogenic effect of
RELAFUS1 is further underscored by a series of mutant forms of
RELAFUS1, where expression programs affecting cell-cell adhe-
sion specifically characterize mutants of this fusion oncogene.
Further, only a subset of residues critical for RELA activity are
essential for oncogenic activity of RELAFUS1. Finally, the amount
of PDGF and its receptor induced by RELAFUS1 in murine ST-3794 Cell Reports 23, 3787–3797, June 26, 2018EPN are comparable with the amounts of these proteins
sufficient to drive oncogenesis in RCAS/tv-a mouse models of
gliomas. It therefore seems possible that at least part of the
oncogenic effect of RELAFUS1 in the CNS includes induction of
PDGF signaling.
Our model faithfully recapitulated the histologic features and
molecular profile of humanRELA fusion-positive ependymomas.
However, given that RELA fusions were generated by a chromo-
thripsis event on chromosome 11, the gene rearrangementmight
affect the status of other genes on the chromosome with various
degrees. Therefore, although RELA fusion alone is sufficient to
form brain tumors in mice, the molecular mechanism underlying
RELA fusion driven-tumorigenesis in humans could be more
complex and influenced by other altered neighboring genes.
The emerging data regarding this tumor type provides the po-
tential for diagnostic tests that clearly distinguish these tumors
from other glial neoplasms. Immunohistochemical analysis of
tumors revealed strong nuclear-localized RELA staining in the
RELAFUS-positive EPN and less nuclear or even nuclear-excluded
RELA staining in the case of other ependymomas and gliomas.
Obviously a more direct measure of the presence of RELAFUS
wouldbeRT-PCR for the various possiblemRNAsencoding these
fusion proteins. Of course, creating such a set of diagnostic tools
would be much more compelling when a therapeutic strategy
aimed at the RELAFUS1 gene product has been developed.
EXPERIMENTAL PROCEDURES
Human Tumor Samples and Patient Characteristics
Formalin-fixed paraffin-embedded (FFPE) human EPN samples (n = 120) were
obtained from the Department of Pathology at the University of Washington
(UW; Seattle, WA; n = 56), Kitasato University (Kanagawa, Japan; n = 51),
and Kanazawa University (Kanazawa, Japan; n = 13). In addition, 30 samples
of surgically resected World Health Organization (WHO) grade IV GBMs were
retrieved from the University of Washington pathology archive and were uti-
lized as control groups. These samples were diagnosed according to the
WHO classification (Louis et al., 2016) and had IRB (institutional review board)
approval at each institution (University of Washington; IR File 8305; Kanazawa
University, 2015-010 [396]; Kitasato University, B13-191). Clinical and patho-
logic characteristics are summarized in Table S2A. Recurrent ependymomas
were categorized in primary sites regardless of the recurrent location in this
study. Several available frozen samples from Kitasato University were also
used for RT-PCR detection of RELAFUS1 and RELAFUS2.
Generation of Murine Brain Tumors
All animal experiments were done in accordance with protocols approved by
the Institutional Animal Care and Use Committees of Fred Hutchinson Cancer
Research Center (FHCRC) and followed NIH guidelines for animal welfare. The
RCAS/tv-a system used in this work has been described previously (Holland
et al., 1998, 2000; Holland and Varmus, 1998; Ozawa et al., 2014). GFAP
(G)/tv-a, Nestin (N)/tv-a (agouti), N/tv-a;Ink4a-Arf/;Ptenfl/fl, or BLBP (B)/tv-a
mice were used for RCAS-mediated brain tumor formation in this study.
Briefly, DF-1 cells were transfected with the indicated RCAS plasmid using
X-tremeGENE 9 DNA transfection reagent (Roche) according to the manufac-
turer’s protocol. After checking RCAS expression with western blotting anal-
ysis, the cells (1 mL of 1 3 105 cells) were injected into newborn pup brains
(within 3 days after birth). Themiceweremonitored until they developed symp-
toms of disease, such as lethargy, poor grooming, weight loss, dehydration,
macrocephaly, seizures, jumping, and paralysis, or until 6 months after injec-
tion. Cases that failed to wean due to severe hydrocephalus caused by injec-
tion trauma and an inflammatory response against DF-1 cells were excluded
from this study. Mouse brains were then used for subsequent analyses such
as survival analysis, immunohistochemistry, and RNA-seq. Kaplan-Meier
analysis demonstrating symptom-free survival of murine brain tumors was
performed using log rank test in the Prism 7 software (GraphPad) for all mice
injected with the relevant RCAS virus. Log rank p values were measured
with the Mantel-Cox test. A value of p < 0.05 was considered significant in
this study.
H&E Staining and Immunohistochemistry
Mouse brains were paraffin-embedded, sectioned, and stained with H&E as
described previously (Hambardzumyan et al., 2009; Holland et al., 2000).
Immunohistochemical staining of mouse brains and human specimens was
performed with an automated staining processor using the Discovery DAB
Map Detection Kit according to standard protocols as described previously
(Ventana Medical Systems, Tucson, AZ) (Hambardzumyan et al., 2008). Forambiguous cases, the staining was repeated and carefully examined. Human
ST-ependymomas were stained at least twice. See also Supplemental Exper-
imental Procedures.
Plasmids
All vectors used in this study are listed in Table S1E. The details of vector con-
structs are described in the Supplemental Experimental Procedures.
Western Blot Analysis
Cells were cultured, lysed, and processed for western blotting by standard
methods. See also Supplemental Experimental Procedures.
RNA-Seq Analysis for Murine Brain Tumors and NIH 3T3T Cells
Tumor tissues and half normal forebrains were macroscopically dissected and
quickly crushed in liquid nitrogen. Total RNAs for mouse tissues and NIH 3T3T
cells were extracted with the RNeasy Mini Kit (QIAGEN) according to the man-
ufacturer’s protocol and then labeled and amplified with the Illumina protocol,
followed by sequencing on Illumina HiSeq2500 at the Genomics Shared
Resource at FHCRC. RNA-seq reads were aligned to the University of Califor-
nia, Santa Cruz (UCSC) mm10 assembly using Tophat2 (Kim et al., 2013) and
counted for gene associations against the UCSC genes database with HTSeq.
Batch effects were corrected using the R function combat from the R package
swamp (https://cran.r-project.org/web/packages/swamp/index.html). Log2
normalized data were used for subsequent principal-component analysis,
MDS, and GSEA in R. Differential expression analysis was performed using
the R/Bioconductor package limma (Ritchie et al., 2015). See also Supple-
mental Experimental Procedures.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the raw sequencing data and read count per gene
data reported in this paper are SRA: SRP096964 and GEO: GSE93765,
respectively. All codes in this study are available upon request.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.04.099.
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